In 1991, the FAB group published a proposal to designate acute leukemias wi
th minimal signs of myeloid differentiation as AML-M0. This proposal was me
ant to offer a provisional basis for the study of immature myeloid forms, w
ith the understanding that it was susceptible to changes and improvements w
ith new information derived from the laboratory. Since then there have been
a number of reports detailing the biological and clinical features of pati
ents with AML-M0. In this article we review the laboratory data acquired fr
om various sources and suggest a partial modification of diagnostic criteri
a. (C) 1999 by Academic Press.